TEVA PHARMACEUTICAL INDUSTRIES LTD. (TEVA) 8-K SUMMARY

This Form 8-K, dated November 5, 2025, serves primarily to announce the release of Teva’s financial results for the Third Quarter ended September 30, 2025.

• Material Event: Item 2.02 reports the issuance of a press release detailing Q3 2025 performance.
• Key Document: Investors must refer to Exhibit 99.1 (“Teva Reports 2025 Third Quarter Financial Results”) for specific financial metrics, revenue figures, and forward-looking guidance.
• Regulatory Note: Information furnished in Item 2.02 is generally not dee